As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

The MHRA said that Novartis' drug warranted inclusion in the EAMS because "despite different available treatment options, patients with heart failure, especially those with reduced ejection ...

With an array of new medicines and medical devices on display global medical companies are looking to tap further into the ...

Welford covers the Healthcare sector, focusing on stocks such as Sanofi, GlaxoSmithKline, and Novartis ... The company sells branded drugs across several major therapeutic classes, including ...

head of global drug development and chief medical officer at Novartis. “People with this inherited risk factor are facing cardiovascular risks that cannot be addressed effectively with lifestyle ...

The majority of U.S. stock indices ended lower on Nov. 12, as rising U.S. treasury yields posed a headwind to the equities’ rally witnessed over the past few days following the election results. The ...

"China market is one of the most attractive markets for Edwards," said Leo Tam, senior director of the business unit of Transcatheter Aortic Valve Replacement, Edwards Lifesciences China, citing a lot ...

Executed global exclusive development and commercialization license agreement with Novartis to advance VAV1-directed molecular ... including immunology and inflammation (I&I), cardiovascular, and ...

SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...

The major players in the market are Hisamitsu Pharmaceuticals, Bayer AG, Novartis AG ... Forecast Global Transdermal Drug Delivery Systems Market Size By Type (Transdermal Patches, Transdermal ...

Bayer Consumer Health Division signed a strategic partnership agreement with the Shandong Institute for Food and Drug Control ...